Results 281 to 290 of about 137,029 (384)

Liver Involvement in Celiac Disease and Immune‐Mediated Diseases of the Small Bowel

Liver International, Volume 45, Issue 8, August 2025.
ABSTRACT Disorders of the hepatobiliary system are commonly associated with gastrointestinal (GI) diseases. The GI and hepatobiliary systems interact through the portal vein system and enterohepatic circulation, creating a gut–liver axis that allows for a complex multidirectional interplay between immune, hormonal, dietary and environmental luminal ...
Nicoletta Nandi, Elena F. Verdu, Detlef Schuppan, Andres Jose Gomez‐Aldana, Maria Ines Pinto‐Sanchez, Francesco Simone Conforti, Marco Maggioni, Flavio Caprioli, Luca Elli   +8 more
wiley   +1 more source

A 50-Year Delay in the Diagnosis of Takayasu Arteritis: Clinical Presentation and Therapeutic Insights. [PDF]

Cureus
Yasuda T, Hagino N.
europepmc   +1 more source

Long-term outcome of patients with steroid-refractory acute severe UC treated with ciclosporin or infliximab

Gut, 2017
D. Laharie, A. Bourreille, J. Branche, M. Allez, Y. Bouhnik, J. Filippi, F. Zerbib, G. Savoye, L. Vuitton, J. Moreau, A. Amiot, J. Cosnes, E. Ricart, O. Dewit, A. lópez-sanromán, M. Fumery, F. Carbonnel, G. Bommelaer, B. Coffin, X. Roblin, G. V. Assche, M. Esteve, M. Färkkilä, J. Gisbert, P. Marteau, S. Nahon, M. D. Vos, J. Lambert, J. Mary, E. Louis   +29 more
semanticscholar   +1 more source

Balinatunfib: A Clinical Oral Small Molecule TNFα Inhibitor

ChemMedChem, Volume 20, Issue 14, July 18, 2025.
Balinatunfib (BNF) is an oral small molecule undergoing clinical trials that stabilizes an asymmetrical TNFα (tumor necrosis factor) trimer. By locking TNF in a nonsignaling conformation, BNF achieves biologic‐like efficacy in preclinical arthritis models, potentially transforming the management of TNF‐driven inflammation. Most diseases are accompanied
Alexander Dömling, Tad A. Holak
wiley   +1 more source

Biosimilar Infliximab in Inflammatory Bowel Disease: Outcomes of a Managed Switching Programme

Journal of Crohn's & Colitis, 2017
Violeta Razanskaite, M. Bettey, L. Downey, Julia Wright, James Callaghan, M. Rush, S. Whiteoak, S. ker, Kim Perry, C. Underhill, E. Efrem, Iftikar Ahmed, F. Cummings   +12 more
semanticscholar   +1 more source

Pharmacology and relevant drug interactions of metamizole

British Journal of Clinical Pharmacology, Volume 91, Issue 7, Page 2095-2102, July 2025.
Metamizole is a frequently prescribed analgesic because of its favourable benefit/risk ratio compared with classic NSAIDs. However, increasing research shows that metamizole displays several drug interactions that are relevant to clinical practice. We reviewed the literature to summarize the pharmacology and most clinically relevant drug interactions ...
David J. Brinkman, Linda C. Hendriksen, Irma M. Rigter, Markus W. Hollmann   +3 more
wiley   +1 more source

Infliximab use and cervical spine deformity in patients with rheumatoid arthritis. [PDF]

RMD Open
Lebouille-Veldman AB, Huizinga TWJ, Mekary RA, Vleggeert-Lankamp CLA.   +3 more
europepmc   +1 more source

PGI16: ANALYSIS OF THE LONG-TERM COSTS, SAVINGS AND EFFECTS GENERATED BY INFLIXIMAB TO NORMALIZE QUALITY OF LIFE IN PATIENTS WITH CROHN'S DISEASE

, 2001
Lieven Annemans, K Moeremans, P. Rutgeerts, Liesbeth Lemmens   +3 more
openalex   +1 more source

Immune Checkpoint Inhibitor‐Related Dysautonomia in Merkel Cell Carcinoma: A Case Report

Cancer Reports, Volume 8, Issue 7, July 2025.
ABSTRACT Background Immune checkpoint inhibitors (ICIs) are monoclonal antibodies that block inhibitory pathways that cancer cells exploit to suppress T‐cell activation. Although immune‐related adverse events (irAEs) linked to ICI therapy are well documented and encompass dermatologic, endocrine, gastrointestinal, hepatic, and neurologic systems, ICI ...
Nidhi Kuchimanchi, Sai Gajula, Elizabeth M. Gaughan, Russell G. Witt   +3 more
wiley   +1 more source

Case Report: Hemolytic anemia secondary to infliximab treatment in a patient with ulcerative colitis. [PDF]

Front Med (Lausanne)
Bevivino G, Scarozza P, Di Fonzo M, Zerboni G, Iacopini F.   +4 more
europepmc   +1 more source